199 related articles for article (PubMed ID: 10336801)
1. Sample size estimation in phase III cancer clinical trials.
Curran D; Sylvester RJ; Hoctin Boes G
Eur J Surg Oncol; 1999 Jun; 25(3):244-50. PubMed ID: 10336801
[TBL] [Abstract][Full Text] [Related]
2. Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.
Halabi S
Urol Oncol; 2008; 26(3):300-7. PubMed ID: 18452825
[TBL] [Abstract][Full Text] [Related]
3. A seamless phase II/III design with sample-size re-estimation.
Bischoff W; Miller F
J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
[TBL] [Abstract][Full Text] [Related]
4. Multiple-arm superiority and non-inferiority designs with various endpoints.
Chang M
Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
[TBL] [Abstract][Full Text] [Related]
5. Sample size estimation for GEE method for comparing slopes in repeated measurements data.
Jung SH; Ahn C
Stat Med; 2003 Apr; 22(8):1305-15. PubMed ID: 12687656
[TBL] [Abstract][Full Text] [Related]
6. On group sequential designs comparing two binomial proportions.
Kepner JL
J Biopharm Stat; 2010 Jan; 20(1):145-59. PubMed ID: 20077254
[TBL] [Abstract][Full Text] [Related]
7. [Interim analyses].
Kramar A; Paoletti X
Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
[TBL] [Abstract][Full Text] [Related]
8. How many do I need? Basic principles of sample size estimation.
Devane D; Begley CM; Clarke M
J Adv Nurs; 2004 Aug; 47(3):297-302. PubMed ID: 15238124
[TBL] [Abstract][Full Text] [Related]
9. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
Stallard N
Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of underpowered randomized clinical trials in rheumatology.
Keen HI; Pile K; Hill CL
J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
[TBL] [Abstract][Full Text] [Related]
11. The unclear zone in phase II clinical trials.
Allegro S; Pond GR; Hotte SJ
Eur J Cancer; 2010 Sep; 46(13):2408-13. PubMed ID: 20580547
[TBL] [Abstract][Full Text] [Related]
12. Flexible two-stage design with sample size reassessment for survival trials.
Desseaux K; Porcher R
Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
[TBL] [Abstract][Full Text] [Related]
13. Biostatistics in clinical trials: Part 2. Determining sample sizes for clinical trials.
Ellenberg SS
Oncology (Williston Park); 1989 Aug; 3(8):39-46; discussion 48, 51. PubMed ID: 2519197
[TBL] [Abstract][Full Text] [Related]
14. Conservative sample size estimation in nonparametrics.
De Martini D
J Biopharm Stat; 2011 Jan; 21(1):24-41. PubMed ID: 21191852
[TBL] [Abstract][Full Text] [Related]
15. Flexible design of two-stage adaptive procedures for phase III clinical trials.
Koyama T
Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
[TBL] [Abstract][Full Text] [Related]
16. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
[TBL] [Abstract][Full Text] [Related]
17. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
18. Design and sample size estimation in clinical trials with clustered survival times as the primary endpoint.
Xie T; Waksman J
Stat Med; 2003 Sep; 22(18):2835-46. PubMed ID: 12953283
[TBL] [Abstract][Full Text] [Related]
19. On sample size calculation for 2x2 fixed-effect ANOVA when variances are unknown and possibly unequal.
Guo JH; Luh WM
Br J Math Stat Psychol; 2009 May; 62(Pt 2):417-25. PubMed ID: 18559139
[TBL] [Abstract][Full Text] [Related]
20. Sample size for two-stage studies with maintenance therapy.
Feng W; Wahed AS
Stat Med; 2009 Jul; 28(15):2028-41. PubMed ID: 19382105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
